1. GLOBOCAN (2020). https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. Accessed 26 Apr 2022
2. Liu, P., Wang, Y., Li, X.: Targeting the untargetable KRAS in cancer therapy. Acta Pharmaceutica Sinica B 9(5), 871–879 (2019)
3. Dinu, D., et al.: Prognostic significance of KRAS gene mutations in colorectal cancer-preliminary study. J. Med. Life 7(4), 581–587 (2014)
4. Humbert, P.O., et al.: TSPAN6 is a suppressor of RAS-driven cancer. Oncogene 41, 2095–2105 (2022)
5. Roa, I., Sánchez, T., Majlis, A., Schalper, K.: Mutación del gen KRAS en el cáncer de colon y recto. Rev. Med. Chil. 141(9), 1166–1172 (2013)